FDA Approval: FLAURA2, First Line Osimertinib Plus Chemotherapy for EGFR NSCLC
Podcast | English | 47 Min
Image For Activity Cover
Cost
$0.00
Credit
No Credit Offered

In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion on the FLAURA2 study and changes in the first-line treatment of EGFR NSCLC with guests Dr. Pasi Jänne and Dr. Marcelo Corassa. FLAURA2 was first presented at the 2023 WCLC in Singapore by Dr. Jänne.

Podcast Hosts:
  • Narjust Florez, MD, Associate Director of the Cancer Care Equity Program and Thoracic Medical Oncologist, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA  

Podcast Guests: 

  • Marcelo Corassa, MD, Medical Oncologist and Researcher, A Beneficência Portuguesa de São Paulo, Brazil
  • Pasi Jänne, MD, PhD, Professor of Medicine, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Powered By